Five companies with connections to Houston have made it on this year’s 100 most influential companies by Time magazine. Photo via Getty Images

Five companies with strong ties to Houston have been named among this year’s 100 most influential companies by Time magazine.

The five companies are:

  • South Korea’s Hanwha Group, whose Hanwha Power Systems Americas subsidiary is in Houston. Hanwha, known as the “Lockheed Martin of Asia,” was praised for winning approval last year from the American Bureau of Shipping for the world’s first large-scale, carbon-free liquefied natural gas (LNG) vessel.
  • Houston-based Intuitive Machines. In February, the company’s Odysseus spacecraft became the first commercial spacecraft to land on the moon. The feat also marked the first U.S. landing on the moon since 1972.
  • Saudi Aramco, whose Americas headquarters is in Houston. Time cited Saudi Aramco’s dominance in the global oil market as a $1.9 billion “giant.”
  • Germany-based ThyssenKrupp Nucera, whose U.S. headquarters is in Houston. The company builds alkaline water electrolyzers to power steel mills and other fossil-fuel-dependent industrial sites.
  • United Airlines, which operates a hub at George Bush Intercontinental Airport. Chicago-based United was lauded for funding startups that help produce sustainable aviation fuel.

To come up with the fourth annual list, Time solicited nominations and polled in-house contributors and correspondents, along with external experts. Editors at Time then evaluated each company based on factors such as impact, innovation, ambition, and success.

“The result is a diverse group of 100 businesses helping chart an essential path forward,” the magazine says.

In a news release, Time’s editor in chief, Sam Jacobs, says the list of 100 companies “is more than an index of business success.”

“It is an argument for what business influence looks like in 2024,” Jacobs adds. “At a time when leadership in other sectors is battered, surveys suggest that many look to corporate leaders first for direction …. Each show us how companies can provide new models and new inspiration for the future of humanity.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.